Concepedia

Author

D B Hunninghake

University of Minnesota

Also Known As

D B Hunninghake, D HUNNINGHAKE, D Hunninghake, D. B. Hunninghake, D. Hunninghake, D.B. Hunninghake, Donald B. Hunninghake

40

Publications

1.4K

Citations

16

H-Index

41

Concepts

All Affiliations

University of MinnesotaMerck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy
DB

About

D B Hunninghake is an author at University of Minnesota specializing in cardiovascular disease, medicine, and atherosclerosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

312

2

Public Health

4

4

88

3

Health Sciences

1

1

175

4

Natural Sciences

1

1

27

5

Biochemistry

1

1

27

D B Hunninghake

×

18

Publications

810

Citations

16

H-Index

YearCitations

Therapeutic response to lovasatain (Mevinolin) in nonfamilial hypercholesterolemia - A Multicenter study

D B Hunninghake, Joanie Larose, Robert H. Palmer,

JAMA

1986

175

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

Peter M. Jones, D B Hunninghake, Keith C. Ferdinand,

Clinical Therapeutics

2004

113

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

Byron J. Hoogwerf, Abdelkarim Waness, Michael D. Cressman,

Diabetes

1999

86

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.

D B Hunninghake, Rebecca G. Bakker-Arkema, J P Wigand,

PubMed

1998

71

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

Rita A. Halpin, E H Ulm, A. E. Till,

Drug Metabolism and Disposition

1993

54

Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.

Anne C. Goldberg, Gustav Schonfeld, E. B. Feldman,

PubMed

1989

52

Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study.

Robert B. Wallace, D B Hunninghake, Susan L. Reiland,

PubMed

1980

40

Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia

Leiv Ose, Michael Davidson, William Insull,

Clinical Cardiology

2000

33

Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy

Maynard L. Freeman, William F. Prigge, D B Hunninghake,

Journal of Lipid Research

1988

27

The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide.

D B Hunninghake, Sontoria D. King, K.A.K. LaCroix

PubMed

1982

27

Page 1